SCYX ▲ +4.0% - SCYNEXIS, Inc.
$SCYX - SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
22-OCT-2026 08:00 AM ET
Share this post
More filings for $SCYX
SCYX ▼ -1.0% - SCYNEXIS, Inc.Oct 21, 2026SCYX ▲ +2.2% - SCYNEXIS, Inc.Oct 6, 2026SCYX ▲ +5.7% - SCYNEXIS, Inc.Sep 28, 2026SCYX ▲ +14.9% - SCYNEXIS, Inc.Sep 28, 2026SCYX ▲ +0.5% - SCYNEXIS, Inc.Sep 22, 2026SCYX ▼ -0.2% - SCYNEXIS, Inc.Sep 10, 2026
View full $SCYX filing history →💬 Comments
Loading comments…
Leave a comment